Naturally acquired SARS-CoV-2 immunity persists for up to 11 months following infection

Valeria De Giorgi1*, Kamille A West1*, Amanda N Henning1, Leonard N Chen1, Michael R Holbrook2, Robin Gross2, Janie Liang2, Elena Postnikova2, Joni Trenbeath1, Sarah Pogue1, Tania Scinto1, Harvey J Alter1, Cathy Conry Cantilena1.

1National Institutes of Health (NIH), Clinical Center, Department of Transfusion Medicine, Bethesda, MD 20892, USA

2National Institute of Allergy and Infectious Diseases (NIAID) Integrated Research Facility, National Institutes of Health (NIH), Frederick, MD 21702, USA

*First co-authors

Corresponding author:
Valeria De Giorgi, Ph. D, Department of Transfusion Medicine, National Institutes of Health Clinical Center, 10 Center Drive, Room 3N317A, Bethesda, MD 20892, USA. Phone (301) 451-6837. Email: valeria.degiorgi@nih.gov

Disclosure: The authors have no conflicts of interest to declare. The views expressed are the authors’ own and do not represent the National Institutes of Health, the Department of Health and Human Services, or the U.S. Federal government.

Summary: A longitudinal serological study of 228 convalescent plasma donors, showing that immunological memory is acquired in most individuals infected with SARS-CoV-2 and is sustained in a majority of patients for up to 11 months after recovery.
ABSTRACT

Background: Characterizing the kinetics of the antibody response to SARS-CoV-2 is of critical importance to developing strategies that may mitigate the public health burden of COVID-19. We conducted a prospective, longitudinal analysis of COVID-19 convalescent plasma (CCP) donors at multiple time points over an 11-month period in order to determine how circulating antibody levels change over time following natural infection. Methods: From April 2020 to February 2021, we enrolled 228 donors. At each study visit, subjects either donated plasma or had study samples drawn only. Anti-SARS-CoV-2 donor testing was performed using the VITROS® Anti-SARS-CoV-2 Total and IgG assays, and an in-house fluorescence reduction neutralization assay (FRNA). Results: Anti-SARS-CoV-2 antibodies were identified in 97% of COVID-19 convalescent donors at initial presentation. In follow up analyses, of the 116 donors presenting for repeat timepoints, 91.4% of donors had detectable IgG levels up to 11 months post-symptom recovery, while 63% had detectable neutralizing titers, however, we observed that 25% of donors had neutralizing levels that dropped to an undetectable titer over time. Conclusion: Our data suggest that immunological memory is acquired in most individuals infected with SARS-CoV-2 and is sustained in a majority of patients for up to 11 months after recovery.

Key Words: COVID-19, serology, neutralizing, convalescent plasma, immunological memory
Introduction

The ongoing COVID-19 pandemic, caused by the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), constitutes a global health crisis with devastating social and economic consequences. As efforts are underway to curtail further spread of COVID-19 worldwide, it is critical to understand the longevity and potency of immune response to SARS-CoV-2. Antibody production represents a significant component of the immune response to SARS-CoV-2, and serologic assays to detect circulating antibody levels are a readily available tool in clinical laboratory settings for tracking immune responses over time [1, 2].

Due to the recent emergence of this infectious disease, there is a relative paucity of data on the long-term kinetics of SARS-CoV-2 antibodies. Studies of individuals who have recovered from natural infection may help to determine how long antibodies persist after an immunizing exposure, and whether or not these antibodies might protect against re-infection. The persistence of antibody response may also help predict the efficacy of vaccines for COVID-19.

COVID-19 convalescent plasma (CCP) is an investigational therapy that remains somewhat controversial, with conflicting reports of efficacy [3, 4, 5]. The underlying principle of this treatment approach is the passive transfer of anti-SARS-CoV-2 antibodies to patients with COVID-19. Serologic assays therefore play a critical role in identifying suitable convalescent plasma donors, and provide evidence of humoral immunity against SARS-CoV-2.

Importantly, as CCP donors may return for multiple repeat donations, these individuals provide a valuable opportunity to characterize anti-SARS-CoV-2 serologic responses and to determine how circulating antibody levels change over time in a well-defined cohort [6].

Of the four major structural proteins for SARS-CoV-2, spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins, the S and the N proteins are both highly immunogenic.
and abundantly expressed during the infection [7]. They have been used as target antigens for the majority of serological assays. The S glycoprotein, however, is surface-exposed and mediates entry into host cells. As such it is subject to a more stringent selection pressure from the immune system, and for this reason, it represents the main target of neutralizing antibodies [8].

In the current study, we prospectively conducted a longitudinal serological assessment of CCP donors after recovery from natural infection. Donors were assessed for levels of neutralizing antibodies as well as total and IgG-specific S protein antibodies using a lab developed fluorescent reduction neutralization assay (FRNA) and a commercially available system (Ortho VITROS®). Data were analyzed to identify correlations between antibody levels and clinical characteristics, and we present follow-up serological data in repeat CCP donors. Collectively, we present a comprehensive view of SARS-CoV-2 antibody dynamics over an 11-month period after natural infection, increasing our understanding of COVID-19 immune responses among persons with community acquired SARS-CoV-2 infection.

Methods

CCP Donor qualification and plasma collection

COVID-19 convalescent plasma donors were prospectively enrolled onto an IRB-approved protocol (Clinical Trials Number: NCT04360278) and provided written informed consent for the study. Eligibility criteria included (1) routine blood donor criteria, (2) molecular or serologic laboratory evidence of past COVID-19 infection and (3) complete recovery from COVID-19, with no symptoms for $\geq 28$ days, or $\geq 14$ days with a negative molecular test after recovery.

We collected donor demographic and biometric data, including age, race, sex and body mass index. We categorized clinical severity of past COVID-19 infection as asymptomatic, mild
(self-limiting course, symptomatic management at home), moderate (emergency room management or hospitalization) or severe (ICU admission). Depending on center-specific logistics and changes in demand for convalescent plasma, at each study visit, subjects either donated plasma, or only had whole blood samples drawn for research; in all cases, anti-SARS-CoV-2 testing was performed. Based on the results of the previous visit, donors were recruited to either continue donating plasma, or donate samples for research purposes. Plasma collections were performed by apheresis, yielding 600 – 825 mL of donor plasma. Sample draws were limited to < 70 mL of whole blood per visit. The minimum interval between plasma donations was 28 days; shorter intervals were acceptable between sample draw visits. Routine plasma donor testing was performed, including standard infectious disease testing, blood group assessment and HLA antibody testing in female donors. Plasma for anti-SARS-CoV-2 testing was isolated from EDTA-anticoagulated human whole blood samples. Samples were processed immediately after collection, centrifuged for 15 min at 2500rpm to separate the plasma phase. The upper plasma layer was extracted, aliquoted and stored at -80°C in our research repository after antibody testing and then shipped on dry ice to the NIH/National Institute of Allergy and Infectious Diseases (NIAID) Integrated Research Facility at Fort Detrick, Maryland, USA, for the in-house assessment of the sample's SARS-CoV-2 neutralization activity. Prior to August 2020, the FDA recommended titers of at least 1:160 for investigational convalescent plasma, but a titer of 1:80 was considered acceptable if higher-titer units were not available. In August 2020, the FDA granted COVID-19 convalescent plasma emergency use authorization; the criteria for high-titer CCP have subsequently been revised several times.
SARS-CoV-2 Immunoassay

Donor samples were tested for SARS-CoV-2 antibodies using the Ortho-Clinical Diagnostics VITROS® Total (IgA/G/M) and IgG COVID-19 Antibody tests following the manufacturer’s package insert instructions (https://www.fda.gov/media/136967/download). Both assays have been granted Emergency Use Authorization (EUA) by the FDA. The Ortho-Clinical Diagnostics anti-SARS-CoV-2 assay is a qualitative ChLIA utilizing luminol-horseradish peroxidase (HRP)-mediated chemiluminescence assay, performed on the VITROS® 3600 automated immunoassay analyzer. The assay involves a two-stage reaction. In the first stage antibodies to SARS-CoV-2 present in the sample bind with SARS-CoV-2, spike protein coated on wells. Any unbound sample is removed by washing. In the second stage, HRP-labeled murine monoclonal anti-human IgG antibodies (or recombinant SARS-CoV-2 spike protein S1 antigen for the total assay) are added in the conjugate reagent. The conjugate binds specifically to the antibody portion of the antigen-antibody complex. If complexes are not present, the unbound conjugate is removed by the subsequent washing step. The HRP in the bound conjugate catalyzed oxidation of the luminol, which produced a chemiluminescent reaction measured by a luminometer. The patient sample signal is divided by the calibrator signal, with the resulting S/Co (Signal/Cutoff) values of <1.00 and ≥1.00 corresponding to nonreactive and reactive results, respectively.

SARS-CoV-2 Neutralizing assay

Assays for determining neutralizing titers were performed with authentic SARS-CoV-2 (2019-nCoV/USA-WA1-A12/2020 from the US Centers for Disease Control and Prevention, Atlanta, GA, USA) at the NIH-NIAID Integrated Research Facility at Fort Detrick, MD, USA using a fluorescence reduction neutralization assay (FRNA) as described by Holbrook et al. [9]. All data were analyzed using Excel. To detect potential experimental errors, we
used Dixon’s Q-test, a quick statistical method to detect gross errors in small samples. We used the critical value of 0.829 for 95% confidence level at N=4 [10, 11].

**Statistical Analysis**

All statistical analyses were performed using GraphPad Prism version 8.4.3 (www.graphpad.com). Relationship between multiple groups were examined using the non-parametric Kruskal-Wallis test, with post hoc comparisons calculated using Dunn’s multiple comparison test. US population demographic data for age and sex were obtained from the 2019 US Census Bureau survey (www.census.gov). Blood type frequencies were obtained from Garratty et al. [12].

**Results**

**COVID-19 Convalescent Plasma Donor Characteristics**

We enrolled 228 COVID-19 convalescent plasma (CCP) donors between April 2020 and February of 2021. The median age of the cohort was 47 (18-79) years, 54.8% of donors were female. The distribution of donor ABO/Rh blood groups was as follow: A+ (31.1%), A- (5.7%), AB+ (7.5%), AB- (0.4%), B+ (12.7%), B- (0.4%), O+ (32.5%) and O- (5.3%), which was not statistically different from the US general population (Fig 1a-c). HLA antibodies were found in 24% of females. The overwhelming majority of donors reported a mild disease course (205, 89.9%). Most donors self-identified as Caucasian (75.9%), Asian (8.3%), Black (6.1%), or Hispanic (3.9%). Additional CCP donor characteristics are shown in Table 1.
SARS-CoV-2 Seroconversion and Neutralizing Activity at Initial Presentation

At first study visit, donors presented at a median of 47.5 (18-315) days post-symptom resolution. Total SARS-CoV-2 antibodies were detected in 96.9% of donors (221/228) and IgG antibodies detected in 91.2% of donors (208/228) (Fig 2a). The median S/Co values of CCP plasma samples using the Ortho total Ab and Ortho IgG assay were 186 (0.1-969) and 8.1 (0.01-30.7), respectively. In 44.3% (101/228) of the donors IgG antibody levels at initial presentation met the current FDA EUA high titer criterion of S/Co ≥ 9.5 when tested with IgG VITROS®.

Total SARS-CoV-2 antibody levels were strongly correlated with IgG antibody levels ($r = 0.7853$, $p = <0.0001$) (Fig 2b). Neutralizing activity as measured by FRNA$_{50}$ was observed in 73.2% of samples (167/228) (Fig 2a). The majority of donors (136, 59.6%) had relatively modest neutralizing activity (FRNA$_{50}$ titer ≤1:80). Specifically, 75 (32.9%) had an FRNA$_{50}$ titer of <1:80, and 61 (26.8%) donors had a titer of 1:80, which prior to August 2020 was the minimum acceptable neutralizing antibody titer for CCP per FDA recommendations. A small proportion of CCP donors had higher neutralizing activity (FRNA$_{50}$ titer >1:80), 19 (8.3%) had an FRNA$_{50}$ titer of 1:160, 9 (3.9%) had a titer of 1:320, and 3 (1.3%) had a titer of 1:640.

In our cohort, a statistically significant difference in mean IgG levels among neutralizing titer groups was observed (Kruskal-Wallis test; $H (5) = 106.1$, $p = <0.0001$). Specifically, average IgG antibody levels were significantly greater in samples with high FRNA$_{50}$ titer (1:80 or higher) than in low titer samples (<1:80) (Fig 2c), suggesting a positive correlation between IgG antibodies and SARS-CoV-2 neutralizing activity. We observed weak correlations between total antibody levels or IgG antibody levels and duration of convalescence (expressed as days post-symptom resolution). Specifically, over time, total antibodies displayed a weak but significant positive correlation ($r = 0.2144$, $p = 0.0012$), while IgG antibodies displayed a weak negative correlation of significance ($r = -0.1612$, $p = 0.0157$).
(Extended data Fig 1a). A statistically significant difference in mean days post-symptom resolution and neutralizing titer was observed (Kruskal-Wallis test; $H(5) = 24.00$, $p = 0.0002$), with post hoc pairwise comparisons suggesting a negative correlation between the two (Extended Data Fig. 1b).

**Correlation of CCP donor Serology Tests and Neutralizing Activity with Clinical Characteristics**

A severe clinical COVID-19 course requiring ICU admission, was associated with increased levels of total and IgG antibodies at initial presentation ($p < 0.0001$ and $p = 0.0003$, respectively). There was a statistical significance association between COVID disease severity and neutralizing antibody titer ($p = 0.0224$) (Fig 3a). Increased IgG antibody levels and neutralizing titers were associated with both increased donor age ($p = 0.0073$ and $p = 0.0191$, respectively) and BMI ($p = 0.0006$ and $p = 0.0012$, respectively) (Fig 3b-c). We observed no associations between total antibody levels, IgG levels, or neutralizing antibody titers and sex, HLA status in females, blood type, or race (Extended Data Fig 1c-f).

**SARS-CoV-2 Antibody Levels in CCP Donors over Time**

116/228 (51%) plasma donors returned for repeat study visits, allowing for IgG and neutralizing antibody analyses at multiple time points. Repeat donor demographics were similar to our overall cohort. Most repeat donors presented 2 (37.9%) or 3 (23.3%) times, 38.8% (n = 45/116) presented for 4 or more study visits (Table 1). The median interval between consecutive visits was 44.5 (12-293) days and between the first and final visit was 109.5 (21-293) days (Fig 4a). Across all repeat donors, the first visit time point occurred at a median of 42.5 (18-244) days post-symptom resolution, and the final time point occurred at a median of 196 (57-322) days post-symptom resolution (Fig 4b).

IgG levels decreased over time in a majority of repeat donors (71.6%, 83/116) but increased in 15.5% (18/116) of donors. IgG levels remained unchanged in 4.3% of donors.
In 8.6% of CCP donors (10/116), IgG levels fell below or remained consistently below the cutoff threshold (S/Co < 1) (Fig 4c, Extended Data Fig 2a). Importantly, of the 10 donors with undetectable IgG levels at their final visit, 4 had undetectable IgG levels at initial presentation and the remaining 6 had very low initial IgG S/Co values (S/Co < 3). For donors whose IgG levels decreased over time, an average decrease of 35.1% ± 20.9% in the S/Co value was observed between the first and final visit. For donors whose IgG levels increased over time, the mean increase in IgG S/Co was 56.2% ± 53.3%.

In our analysis of SARS-CoV-2 neutralizing antibody titers over time, for 23.3% (27/116) of repeat CCP donors the FRNA_{50} titers decreased, and increased in only 7.8% (9/116) of donors. In 31.9% (37/116) of donors, neutralizing antibody titers remained unchanged over time or leveled off to a detectable titer for two or more consecutive final time points. Importantly, 37.1% (43/116) of donors, had no detectable neutralizing activity over time (n=14) or had titers fall to undetectable levels (n=29) (Fig 4d). We observed a striking relationship between neutralizing titer levels at first assessment and titer outcome over time. In general, donors with lower initial FRNA_{50} titers (<1:80) were more likely to lose neutralizing activity over time, while donors with higher starting titers were more likely to have their titer levels remain constant or level off over time (Extended Data Fig 2b). This can be seen when repeat CCP donors are stratified based on low (< 1:80) or high (> 1:80) starting titer levels at the initial study visit. For CCP donors with low initial neutralizing titer, 58.2% of donors (32/55) lost neutralizing activity or had titers that remained undetectable over time, compared to 18.0% (11/61) of high titer CCP donors. Conversely, 34.4% of high neutralizing titer donors (21/61) compared to 29.1% of low titer donors (16/55) had titers that remained unchanged or leveled off over time (Fig 4e). Additionally, in the high neutralizing titer group, the majority of donors saw their titer levels decrease over time (44.3%, 27/61). It remains to be seen whether titers would continue to fall for these donors, or would level off over time.
additional time points. Of note, no SARS-CoV-2 re-infection was observed in the study cohort.

Discussion

SARS-CoV-2 has infected millions of individuals globally and, as of February 2021, has led to the death of > 2 million individuals (https://coronavirus.jhu.edu) worldwide. One of the reason for the explosive increase in cases is the limited pre-existing immunity to the virus. As the vaccination, effort around the world began with multiple vaccine types and candidates, evolving variants add complexity to the plan to outrun the virus by vaccination. Cases of re-infections began to be reported in late 2020 [13, 14, 15]. Most of the reported re-infections were far less severe than the first infection in those early reports, boosting the optimistic hypothesis that immune memory of the millions COVID-19 survivors would be able to contribute to the herd immunity to tame the pandemic. However, Zucman et al. described a somber case that is an exception to those mild reinfections described to date, reporting a more severe re-infection caused by the South African variant 20H/501Y.V2 (B.1.351) [16].

As shown from studies of common human coronaviruses, neutralizing antibodies are induced and can last for years, providing protection from re-infection or, in some cases, from aggressive disease [17]. Less definitive data are available for SARS-CoV-2, and the emergence of multiple viral variants and the potential for more severe re-infection underscores the need to better understand the body’s natural immune response to SARS-CoV-2. Undoubtedly, a better understanding of antibody kinetics and protective immunity will be critical in terms of protection against reinfection, for public health policy and vaccine development for COVID-19. To begin to address these questions, we conducted a prospective, longitudinal analysis of 228 COVID-19 convalescent plasma (CCP) donors with
multiple time points over an 11-month period. Studying recovered individuals provides an important opportunity to investigate both antiviral antibody quantification and population immunity conferred after exposure to SARS-CoV-2. Additionally, having repeat serological assessments allowed for the investigation of how circulating antibody levels change over time following natural infection.

At initial assessment, total and IgG SARS-CoV-2 antibodies were detected in 96.9% and 91.2% of donors respectively. Total SARS-CoV-2 antibody levels were strongly correlated with IgG antibody levels, and neutralizing activity was observed in 73.2% of donors.

Our study suggests that most CCP plasma donors, regardless of COVID-19 disease severity, have antibodies to SARS-CoV-2 and more than 70% possess neutralizing antibodies. Notably, and in accordance with already published studies, we have observed a considerable range in antibody titers in recovered COVID-19 donors [18-19].

When correlating IgG antibody levels and neutralizing titers with the clinical picture, our results are consistent with previously published data, observing positive correlation with disease severity [20-26], age [24-26], and BMI [27]. While some reports observed a correlation between antibody levels and male sex [25, 26, 28], we did not observe a statistically significant association in our study. This may be due to the predominantly mild symptomatic nature of our cohort, as males are also more likely to develop severe COVID-19 [29], presenting a potential confounding factor.

Longitudinal analyses of 116 CCP donors revealed that 91.4% of donors had detectable IgG levels up to 11 months after recovery. Although the majority of repeat donors demonstrated a decrease in IgG levels over follow up, IgG levels decreased by only 35.1% on average, and seroreversion to negative was uncommon. Indeed, of the 8.6% of donors with undetectable IgG levels at their final study visit, just under half of these had no detectible IgG
at the initial collection, while the rest represented cases of seroreversion (overall seroreversion rate of 5.2%). It is unlikely that the decline in IgG level was related to the number or frequency of plasma donations in this cohort, since in general, IgG levels do not appreciably decrease over the course of a few months of infrequent plasma donation [30].

However, IgG levels increased in 15.5% (18/116) of plasma donors returned for repeat study visits, and a constant high antibody titer was present up to 293 days from the first donation. IgG levels showed an increase at the last donation that ranged from 10 to 15 (median values) S/CO value. Could be that in these donors the seroconversion took longer time to mount, in particular considering they were all mild cases.

With respect to neutralizing antibodies, SARS-CoV-2 neutralizing antibody levels tended to remain detectable, irrespective of the disease severity. We found that 63% of donors had detectable neutralizing titers up to 11 months post-recovery, with 25% of donors seroreverting, and 12% of donors failing to make detectible neutralizing antibody titers over the course of the study. Although we have observed a decrease in plasma neutralizing activity over time, neutralizing antibody titers remained measurable in a majority of donors.

Importantly, we observed that if donors were stratified based on their titer level at initial assessment, 82% of donors with high starting titer (>1:80) maintained detectible titers over time, while this dropped to 41.8% for those with low starting titer (<1:80). Therefore, our data suggest that neutralizing activity in the early convalescent period may be predictive of long-term neutralizing activity retention. The levels of neutralizing antibody activity required to prevent SARS-CoV-2 re-infection are currently unknown. In our cohort, no SARS-CoV-2 re-infection was identified.

Our results support sustained immunological memory for most of the first year following SARS-CoV-2 infection, even for mild COVID-19 cases, consistent with other reports [31-33].
Furthermore, our data suggest that circulating IgG and neutralizing antibodies persist in most healthy people over the first year following symptom resolution, and longer-term follow-up studies by others have observed similar results out to 8 months [34-38]. However, other reports have observed a decline in immunological response over the first months following symptom resolution, particularly in mild and asymptomatic cases [39-41]. Such discordances could have major implications for modelling of disease transmission, herd immunity and vaccine strategies. Following SARS-CoV-2 infection, B and T cells maintain immunological memory, which enables quicker and stronger response on the subsequent encounter with same or related pathogen and might contribute to herd immunity. Some authors suggest that antibodies confer protective immunity against future SARS-CoV-2 infection [43]; however, the strength and durability of this protection is unknown. In our CCP donor cohort we observed sustained immune memory, with IgG and neutralizing antibodies detected up to 11 months after recovery, supporting the notion that naturally infected patients may have the ability to combat reinfection. The role of non-neutralizing SARS-CoV-2 antibodies is unclear, however they may confer in vivo protection and do not appear to be associated with antibody-dependent enhancement (ADE). More evidence is emerging about the role of cellular responses in protective immunity against COVID-19. Recent studies showed highly functional T cell-mediated response even in individuals who did not mount an antibody response after SARS-CoV-2 infection [44]. Efforts are underway to identify the correlates of immunological protection through studying animal models, variable disease outcomes and preexisting immunity to other coronaviruses [45].
Author Contributions

K.W. conceived, designed and supervised clinical protocols. V.D.G conceived, designed and supervised the research study. ANH performed statistical analysis and generated all paper figures. L.C., S.P. and T.S. recruited participants, executed clinical protocols and collected clinical data. JT provided oversight to clinical sample processing and testing. R.G., J.L. and ENP performed the neutralization assays. M.R.H. provided oversight to neutralization work experiments and critically reviewed the manuscript. V.D.G., K.W., A.N.H and L.C. wrote and critically reviewed the manuscript with input from all co-authors. HJA and CCC critically reviewed the manuscript.

Acknowledgements

The authors thank NIH blood donors for their participation in the study. This work was supported by the Intramural Research Program of the NIH Clinical Center (project Z99 CL999999).

This project has been funded in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN272201800013C. R.G., J.L., and M.R.H. performed this work as employees of Laulima Government Solutions, LLC while E.P performed this work as an employee of Tunnell Government Services.

Conflicts of Interest

The authors have no relevant conflicts of interest to disclose.
Figures legend

**Fig. 1 – COVID-19 convalescent plasma donor characteristics.** a. Age distribution of COVID-19 convalescent plasma (CCP) donors (blue; n=228) relative to the US population (red). Dotted lines represent a Gaussian distribution and the coefficient of determination ($R^2$) was calculated for the CCP goodness of fit. b. Sex distribution of CCP donors (blue; n=228) relative to the US population (red). Binomial test not significant relative to the US population. c. Blood type distribution of CCP donors (blue; n=218) relative to the US population (red). Binomial tests performed relative to US population, all comparisons not significant following Bonferroni correction for multiple comparisons.

**Fig. 2 – SARS-CoV-2 seroconversion and neutralizing activity at initial donation.** a. Percent of CCP donors testing positive (Pos) or negative (Neg) for the presence of total antibodies (Total Ab), IgG antibodies (IgG Ab), or neutralizing antibodies (Neu Ab). b. Correlation of total antibody levels with IgG antibody levels (n=228). Line represents a linear fit of the data including 95% CI (dotted lines). Pearson correlation coefficient (r) is displayed along with p-value. c. Distribution of IgG antibody levels based on FRNA$_{50}$ neutralizing antibody titers (n=228). Boxplots indicate median value with 1$^{st}$ and 3$^{rd}$ quartiles, and bars span minimum and maximum values. Individual patient values are indicated by dots. A statistically significant difference between groups was determined via Kruskal-Wallis test (p-value $<$0.0001). Post hoc comparisons were calculated using Dunn’s multiple comparison test, with significant pairwise comparisons indicated on the graph. S/Co, signal to cutoff ratio; *, p $<$0.05; **, p $<$0.01; ***, p $<$0.001; ****, p $<$0.0001.
Fig. 3 – Correlation of serology tests and neutralizing activity with clinical characteristics. Total antibody levels, IgG antibody levels, and neutralizing antibody titers (FRNA₅₀) in CCP donors are shown based on a. clinical disease course (asymptomatic, n=4; mild, n=205; moderate, n=16; severe, n=3), b. donor age (19-34yo, n=55; 35-54yo, n=89; 55-79yo, n=84), and c. donor BMI (<18.5, n=1; 18.5-24.9, n=87; 25-29.9, n=84; ≥30, n=55; missing data for n=1 donor). For all graphs, boxplots display the median with 1st and 3rd quartiles, and bars span minimum and maximum values. Individual patient values are indicated by dots. Statistically significant differences between groups were determined via Kruskal-Wallis test for total ab levels and IgG ab levels based on disease course (p = <0.0001 and 0.0003, respectively) (a), for IgG ab levels and neutralizing titers based on age (p-value = 0.0073 and 0.0191, respectively) (b), and for IgG ab levels and neutralizing titers based on BMI (p-value = 0.0006 and 0.0012, respectively) (c). Post hoc comparisons were calculated using Dunn’s multiple comparison test, with significant pairwise comparisons indicated on graphs. *, p < 0.05; **, p < 0.01.

Fig. 4 – SARS-CoV-2 antibody levels in CCP donors over time. a. Boxplots indicate the interval between consecutive donations and between first and final donation. b. Boxplots display median number of days post-symptom resolution at indicated donations. For a and b, boxplots indicate median value with 1st and 3rd quartiles, and bars span minimum and maximum values. Individual patient values indicated by dots. c. IgG antibody outcomes over time for repeat CCP donors are quantified in the pie chart, and individual antibody levels are plotted relative to days post-symptom resolution (n=114; n=2 asymptomatic donors not plotted). Only first and last CCP donation values are plotted. Samples from the same donor connected by lines. Colors indicate antibody level outcomes over time: increase (green), decrease (red), no change (percent change <1%; purple), and negative (levels consistently
below or falling below cutoff threshold S/Co <1; black). The S/Co threshold of 1 indicated by
the dashed line. Values below this threshold are represented by an “x”.

d. Neutralizing titer outcomes over time for repeat CCP donors are quantified. Outcome categories are the same
as in e, except: No change/Level off indicates donors whose titers remained unchanged or
leveled off to a detectable titer (≥1:40) for their last 2 or more donations, and Negative
indicates donors with consistently undetectable activity or whose titers fell to an undetectable
level (<1:40).
e. Outcomes from d stratified based on the titer at first donation. S/Co, signal
to cutoff ratio.
References

1. Jiang XL, Wang GL, Zhao XN, Yan FH, Yao L, Kou ZQ, et al. Lasting antibody and T cell responses to SARS-CoV-2 in COVID-19 patients three months after infection. Nat Commun. 2021;12(1):897.

2. Byazrova M, Yusubalieva G, Spiridonova A, Efimov G, Mazurov D, Baranov K, et al. Pattern of circulating SARS-CoV-2-specific antibody-secreting and memory B-cell generation in patients with acute COVID-19. Clin Transl Immunology. 2021;10(2):e1245.

3. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA. 2020;323(16):1582-9.

4. Cantore I, Valente P. Convalescent plasma from COVID 19 patients enhances intensive care unit survival rate. A preliminary report. Transfus Apher Sci. 2020;59(5):102848.

5. Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA. 2020;324(5):460-70.

6. Muecksch F, Wise H, Batchelor B, Squires M, Semple E, Richardson C, et al. Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients. J Infect Dis. 2021;223(3):389-98.

7. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020;181(2):281-92 e6.

8. Liu W, Liu L, Kou G, Zheng Y, Ding Y, Ni W, et al. Evaluation of Nucleocapsid and Spike Protein-Based Enzyme-Linked Immunosorbent Assays for Detecting Antibodies against SARS-CoV-2. J Clin Microbiol. 2020;58(6).
9. Holbrook, MR. et al. Scalable, Micro-Neutralization Assay for Qualitative Assessment of SARS-CoV-2 (COVID 19) Virus-Neutralizing Antibodies in Human Clinical Samples. bioRxiv. posted 5 March 2021, 10.1101/2021.03.05.434152

10. Dean, R.B. and Dixon W.J, Simplified Statistics for Small Numbers of Observations. Analytical Chemistry, 1951. 23(4): p. 636-638.

11. Rorabacher, D.B. Statistical treatment for rejection of deviant values: critical values of Dixon's "Q" parameter and related subrange ratios at the 95% confidence level. Analytical Chemistry, 2002. 63(2): p. 139-146.12.

12- Garratty G, Glynn SA, McEntire R, Retrovirus Epidemiology Donor S. ABO and Rh(D) phenotype frequencies of different racial/ethnic groups in the United States. Transfusion. 2004;44(5):703-6.

13- Selvaraj V, Herman K, Dapaah-Afriyie K. Severe, Symptomatic Reinfection in a Patient with COVID-19. R I Med J (2013). 2020;103(10):24-6.

14- To KK, Hung IF, Chan KH, Yuan S, To WK, Tsang DN, et al. Serum antibody profile of a patient with COVID-19 reinfection. Clin Infect Dis. 2020.

15- To KK, Hung IF, Ip JD, Chu AW, Chan WM, Tam AR, et al. COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing. Clin Infect Dis. 2020.

16- Zucman N, Uhel F, Descamps D, Roux D, Ricard JD. Severe reinfection with South African SARS-CoV-2 variant 501Y.V2: A case report. Clin Infect Dis. 2021.

17- Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220-32

18- Huang AT, Garcia-Carreras B, Hitchings MDT, Yang B, Katzelnick LC, Rattigan SM, et al. A systematic review of antibody mediated immunity to coronaviruses:
kinetics, correlates of protection, and association with severity. Nat Commun. 2020;11(1):4704.

19- Benner SE, Patel EU, Laeyendecker O, Pekosz A, Littlefield K, Eby Y, et al. SARS-CoV-2 Antibody Avidity Responses in COVID-19 Patients and Convalescent Plasma Donors. J Infect Dis. 2020;222(12):1974-84.

20- Wu F, Liu M, Wang A, Lu L, Wang Q, Gu C, et al. Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China. JAMA Intern Med. 2020;180(10):1356-62.

21- Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26(8):1200-4.

22- Ko JH, Joo EJ, Park SJ, Baek JY, Kim WD, Jee J, et al. Neutralizing Antibody Production in Asymptomatic and Mild COVID-19 Patients, in Comparison with Pneumonic COVID-19 Patients. J Clin Med. 2020;9(7).

23- Lei Q, Li Y, Hou HY, Wang F, Ouyang ZQ, Zhang Y, et al. Antibody dynamics to SARS-CoV-2 in asymptomatic COVID-19 infections. Allergy. 2021;76(2):551-61.

24- Chen Y, Zuiani A, Fischinger S, Mullur J, Atyeo C, Travers M, et al. Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production. Cell. 2020;183(6):1496-507 e16.

25- Robbiani DF, Gaebler C, Muecksch F, Lorenzi JCC, Wang Z, Cho A, et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020;584(7821):437-42.

26- Boonyaratanakornkit J, Morishima C, Selke S, Zamora D, McGuffin S, Shapiro AE, et al. Clinical, laboratory, and temporal predictors of neutralizing antibodies against
SARS-CoV-2 among COVID-19 convalescent plasma donor candidates. J Clin Invest. 2021;131(3).

27- Racine-Brzostek SE, Yang HS, Jack GA, Chen Z, Chadburn A, Ketas TJ, et al. Post Convalescent SARS-CoV-2 IgG and Neutralizing Antibodies Are Elevated in Individuals with Poor Metabolic Health. J Clin Endocrinol Metab. 2021.

28- Bwire GM. Coronavirus: Why Men are More Vulnerable to Covid-19 Than Women? SN Compr Clin Med. 2020;1-3.

29- Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell L, Chernyak Y, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369:m1966.

30- Burgin M, Hopkins G, Moore B, Nasser J, Richardson A, Minchinton R. Serum IgG and IgM levels in new and regular long-term plasmapheresis donors. Med Lab Sci. 1992;49(4):265-70.

31- Terpos E, Mentis A, Dimopoulos MA. Loss of Anti-SARS-CoV-2 Antibodies in Mild Covid-19. N Engl J Med. 2020;383(17):1695.

32- Mateus J, Grifoni A, Tarke A, Sidney J, Ramirez SI, Dan JM, et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science. 2020;370(6512):89-94.

33- Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science. 2020;370(6521):1227-30.

34- Jiang XL, Wang GL, Zhao XN, Yan FH, Yao L, Kou ZQ, et al. Lasting antibody and T cell responses to SARS-CoV-2 in COVID-19 patients three months after infection. Nat Commun. 2021;12(1):897.
35- Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371(6529).

36- Lau EHY, Tsang OTY, Hui DSC, Kwan MYW, Chan WH, Chiu SS, et al. Neutralizing antibody titres in SARS-CoV-2 infections. Nat Commun. 2021;12(1):63.

37- Marot S, Malet I, Leducq V, Zafilaza K, Sterlin D, Planas D, et al. Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers. Nat Commun. 2021;12(1):844.

38- Ibarrondo FJ, Fulcher JA, Goodman-Meza D, Elliott J, Hofmann C, Hausner MA, et al. Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. N Engl J Med. 2020;383(11):1085-7.

39- Wu F, Liu M, Wang A, Lu L, Wang Q, Gu C, et al. Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China. JAMA Intern Med. 2020;180(10):1356-62.

40- Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26(8):1200-4.

41- Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell. 2020;181(7):1489-501 e15.

42- Priyanka, Om Prakash Choudhary Indraj Singh: Protective immunity against COVID-19: Unravelling the evidences for humoral vs. cellular components Travel Med Infect Dis Jan-Feb 2021;39:101911.
43- Harvey RA, Rassen JA, Kabelac CA, Turenne W, Leonard S, Klesh R, et al. Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection. JAMA Intern Med. 2021 May 1;181(5):672-679.

44- Nelde A, Bilich T, Heitmann JS, Maringer Y, Salih HR, Roerden M, et al. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. Nat Immunol. 2021;22(1):74-85.

45- Kang CK, Kim M, Lee S, Kim G, Choe PG, Park WB, Kim NJ, Lee CH, Kim IS, Jung K, Lee DS, Shin HM, Kim HR, Oh MD. Longitudinal Analysis of Human Memory T-Cell Response according to the Severity of Illness up to 8 Months after SARS-CoV-2 Infection. J Infect Dis. 2021 Mar 23: jia159.
| Table 1 - CCP Donor Characteristics | All Donors (n=228) | Repeat Donors (n=116) |
|-------------------------------------|--------------------|-----------------------|
| **Sex**                            | N (%)              | N (%)                 |
| Female                             | 125 (54.8)         | 64 (55.1)             |
| Male                               | 103 (45.2)         | 52 (44.9)             |
| **Disease Course**                 | N (%)              | N (%)                 |
| Asymptomatic                       | 4 (1.8)            | 2 (1.7)               |
| Mild                               | 205 (89.9)         | 103 (88.8)            |
| Moderate                           | 16 (7.0)           | 9 (7.8)               |
| Severe                             | 3 (1.3)            | 2 (1.7)               |
| **Race**                           | N (%)              | N (%)                 |
| Asian                              | 19 (8.3)           | 8 (6.9)               |
| Black                              | 14 (6.1)           | 4 (3.4)               |
| Caucasian                          | 173 (75.9)         | 88 (75.9)             |
| Hispanic                           | 9 (3.9)            | 8 (6.9)               |
| Mixed Race                         | 7 (3.1)            | 4 (3.4)               |
| Other/Unknown                      | 4 (1.8)            | 3 (2.6)               |
| Declined                           | 2 (0.9)            | 1 (0.9)               |
| **Blood Type**                     | N (%)              | N (%)                 |
| A-                                 | 13 (5.7)           | 8 (6.9)               |
| A+                                 | 71 (31.1)          | 36 (31.0)             |
| AB-                                | 1 (0.4)            | 1 (0.9)               |
| AB+                                | 17 (7.5)           | 8 (6.9)               |
| B-                                 | 1 (0.4)            | 1 (0.9)               |
| B+                                 | 29 (12.7)          | 16 (13.8)             |
| O-                                 | 12 (5.3)           | 5 (4.3)               |
| O+                                 | 74 (32.5)          | 41 (35.3)             |
| Unknown                            | 10 (4.4)           | -                     |
| **HLA status in Females**          | N (%)              | N (%)                 |
| Negative                           | 91 (72.8)          | 49 (76.6)             |
| Positive                           | 30 (24.0)          | 14 (21.9)             |
| Unknown                            | 4 (3.2)            | 1 (1.5)               |
| **Median (Range)**                 |                    |                       |
| Age                                | 47 (18-79)         | 50.5 (19-79)          |
| BMI                                | 26.1 (17.9-51.8)   | 26.1 (17.9-51.8)      |
| **Days post-symptom resolution**   |                    |                       |
| 1st donation                       | 47.5 (18-315)      | 42.5 (18-244)         |
| 2nd donation                       | -                  | 105 (53-321)          |
| 3rd donation                       | -                  | 159 (88-322)          |
| Days between | Median (Range) | Median (Range) |
|--------------|----------------|----------------|
| Consecutive donations - | 44.5 (12-293) | |
| 1st and final donation - | 109.5 (21-293) | |

| # of Donations | N (%) | N (%) |
|----------------|-------|-------|
| 2 donation - | 44 (37.9) | |
| 3 donations - | 27 (23.3) | |
| 4 donations - | 23 (19.8) | |
| 5 donations - | 10 (8.6) | |
| 6 donations - | 8 (6.9) | |
| 7 donations - | 2 (1.7) | |
| 8 donations - | 1 (0.9) | |
| 9 donations - | 1 (0.9) | |

*mild*= self-limiting course, symptomatic management at home; *moderate*= emergency room management or hospitalization; *severe*= ICU admission
Figure 1a

Number of Donors

Age Range

R² = 0.7030

% of Population

Downloaded from https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiab295/6293992 by guest on 11 June 2021
Figure 2b

IgG Ab levels (S/Co) vs. Total Ab levels (S/Co)

$r = 0.7853$
$p = < 0.0001$
Figure 3a-b-c
Figure 4d

- All donors: N=116
  - Increase: 37.1%
  - Decrease: 7.8%
  - No change: Level of titer (≥ 1:140) 58.2%

- Low starting titer (<1:180): N=55
  - Increase: 78.1%
  - Decrease: 12.7%
  - No change: Level of titer (≥ 1:140) 29.1%

- High starting titer (≥1:180): N=61
  - Increase: 34.4%
  - Decrease: 18.0%
  - No change: Level of titer (≥ 1:140) 44.3%